NASDAQ:HUGE FSD Pharma (HUGE) Stock Price, News & Analysis → The A.I. story nobody is telling you (Read ASAP) (From TradeSmith) (Ad) Free HUGE Stock Alerts $0.47 +0.01 (+2.16%) (As of 04/25/2024 ET) Add Compare Share Share Today's Range$0.45▼$0.5250-Day Range$0.46▼$1.0652-Week Range$0.42▼$1.68Volume832,488 shsAverage Volume145,625 shsMarket Capitalization$18.61 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get FSD Pharma alerts: Email Address Ad WealthPressIt’s now possible to know the win rate of every trade… BEFORE you take it! Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets. >> You can grab your FREE, laminated copies right here << About FSD Pharma Stock (NASDAQ:HUGE)FSD Pharma Inc., a biotechnology company, operates in the pharmaceutical research and development business. Its lead candidate is FSD-201, an ultra-micronized palmitoylethanolamide for the treatment of inflammatory diseases. The company is also involved in the research and development of Lucid-Psych, a molecular compound identified for the treatment of mental health disorders; and Lucid-MS, a molecular compound identified for the treatment of neurodegenerative disorders. FSD Pharma Inc. was incorporated in 1998 and is headquartered in Toronto, Canada.Read More HUGE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HUGE Stock News HeadlinesApril 23, 2024 | finance.yahoo.comUS to provide 'significant' new security assistance for Ukraine, Biden tells ZelenskiyApril 23, 2024 | news.yahoo.comI’m a doctor in Haiti. Crisis may be death sentence for many with health problems | OpinionApril 25, 2024 | DTI (Ad)A new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… April 23, 2024 | americanbankingnews.comFSD Pharma (NASDAQ:HUGE) Stock Price Up 4.8%April 22, 2024 | finanznachrichten.deFSD Pharma Inc.: FSD Pharma Provides Another Update on Celly Nu's Anticipated Launch of unbuzzdApril 18, 2024 | msn.comSaudi Arabia Earns Top Marks in Global AI Index for National StrategyApril 18, 2024 | seekingalpha.comTesla Stock: Plunging Toward My Price TargetApril 17, 2024 | uk.investing.comFSD Pharma boosts loan to Celly Nutrition for new beverageApril 25, 2024 | WealthPress (Ad)It’s now possible to know the win rate of every trade… BEFORE you take it! Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets. April 8, 2024 | msn.comTesla markets its FSD V12 with impressive real-world resultsMarch 29, 2024 | msn.comWalgreens’ frail quarter goes beyond the discretionary spending dips afflicting its competitors. It’s ‘just not very good at retailing,’ analyst saysMarch 28, 2024 | msn.comTesla stock slips as analysts issue a fresh round of warnings on Q1 deliveriesMarch 16, 2024 | benzinga.comPsychedelics Headlines: Substitution Survey, Frank Herbert's Magic Mushrooms, Celestial Plans And News ReviewMarch 14, 2024 | msn.comMadrigal and liver drug developers fall ahead of FDA decision on NASH therapyMarch 11, 2024 | finance.yahoo.comFSD Pharma Submits a Phase-1b Clinical Trial Application for Ethics Committee for its Proprietary Beverage unbuzzd(TM)March 7, 2024 | investing.comFSD Pharma reports positive Phase-1 MS drug trial resultsMarch 5, 2024 | finance.yahoo.comFSD Pharma Presents Positive Results on First-In-Human Phase-1 study of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2024 ForumFebruary 17, 2024 | finance.yahoo.comHUGE Mar 2024 1.000 callFebruary 16, 2024 | finanznachrichten.deFSD Pharma Inc.: FSD Pharma Announces US ATM OfferingFebruary 16, 2024 | finance.yahoo.comFSD Pharma Announces US ATM OfferingFebruary 6, 2024 | msn.comBig Pharma Targets Smaller Companies With Megadeals Out of FavorFebruary 6, 2024 | finanznachrichten.deFSD Pharma Inc.: Court of Appeal Dismisses Motion for Leave to Appeal Brought by Dr. Raza Bokhari, FSD Pharma Awards Total Approximately $3 MillionFebruary 6, 2024 | finance.yahoo.comCourt of Appeal Dismisses Motion for Leave to Appeal Brought by Dr. Raza Bokhari, FSD Pharma Awards Total Approximately $3 MillionFebruary 3, 2024 | investing.comFSD Pharma Inc Class B (HUGE)February 2, 2024 | msn.comTwo women injured in northeast Memphis crashFebruary 2, 2024 | techcrunch.comPitch Deck Teardown: PhageLab’s $11M Series A deckJanuary 29, 2024 | finanznachrichten.deFSD Pharma Inc.: FSD Pharma Announces Dr. Sanjiv Chopra is elected to FSD Pharma Board of Directors and Corporate UpdatesSee More Headlines Receive HUGE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for FSD Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/28/2024Today4/25/2024Next Earnings (Estimated)5/10/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:HUGE CUSIPN/A CIK1771885 Webfsdpharma.com Phone(416) 854-8884FaxN/AEmployees17Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.47) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-17,900,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-112.38% Return on Assets-82.46% Debt Debt-to-Equity RatioN/A Current Ratio2.43 Quick Ratio2.43 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.33 per share Price / Book1.43Miscellaneous Outstanding Shares39,380,000Free Float36,018,000Market Cap$18.61 million OptionableOptionable Beta0.59 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. Zeeshan Saeed (Age 54)Founder, CEO, President & Executive Co-Chairman Comp: $375.98kMr. Anthony John Durkacz (Age 48)Founder & Executive Co-Chairman Comp: $375.98kMr. Nathan Coyle CPA (Age 43)Chief Financial Officer Comp: $191.89kMr. Donal Carroll CPA (Age 47)Chief Operating Officer Comp: $375.98kDr. Lakshmi P. Kotra BPHARM (Age 53)Ph.D., CEO of Lucid & Director Comp: $331.51kDr. Andrzej Chruscinski M.D.Ph.D., Vice President of Clinical & Scientific Affairs of LucidMr. Kevin CassidyVice President of Quality-LucidMs. Maryann AdessoCorporate SecretaryRandell MackPresident of FSD BioSciencesMore ExecutivesKey CompetitorsKALA BIONASDAQ:KALANeuroSense TherapeuticsNASDAQ:NRSNFlora GrowthNASDAQ:FLGCOrgenesisNASDAQ:ORGSBenitec BiopharmaNASDAQ:BNTCView All CompetitorsInstitutional OwnershipAdvisorShares Investments LLCBought 34,679 shares on 2/14/2024Ownership: 0.687%Scotia Capital Inc.Bought 61,273 shares on 2/12/2024Ownership: 0.156%View All Institutional Transactions HUGE Stock Analysis - Frequently Asked Questions How have HUGE shares performed in 2024? FSD Pharma's stock was trading at $0.9198 at the start of the year. Since then, HUGE shares have decreased by 48.6% and is now trading at $0.4727. View the best growth stocks for 2024 here. Are investors shorting FSD Pharma? FSD Pharma saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 374,000 shares, an increase of 12.2% from the March 31st total of 333,400 shares. Based on an average trading volume of 149,300 shares, the days-to-cover ratio is presently 2.5 days. Currently, 1.1% of the shares of the stock are short sold. View FSD Pharma's Short Interest. When is FSD Pharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our HUGE earnings forecast. How were FSD Pharma's earnings last quarter? FSD Pharma Inc. (NASDAQ:HUGE) posted its earnings results on Thursday, March, 28th. The company reported ($0.04) EPS for the quarter. What other stocks do shareholders of FSD Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other FSD Pharma investors own include Aurora Cannabis (ACB), Acasti Pharma (ACST), Allena Pharmaceuticals (ALNA), Assertio (ASRT), Bionano Genomics (BNGO), Ideanomics (IDEX), Stealth BioTherapeutics (MITO), Millendo Therapeutics (MLND), 9 Meters Biopharma (NMTR) and Selecta Biosciences (SELB). How do I buy shares of FSD Pharma? Shares of HUGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:HUGE) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchThe only accurate crypto trading system I know …Weiss RatingsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding FSD Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
